HomeJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
$111.13
Makalipas ang Oras ng Trabaho:(0.00%)0.00
$111.13
Sarado: Hun 6, 5:20:00 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$108.80
Sakop ng araw
$108.93 - $111.84
Sakop ng taon
$95.49 - $148.06
Market cap
6.85B USD
Average na Volume
1.21M
P/E ratio
14.81
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 897.84M | -0.46% |
Gastos sa pagpapatakbo | 849.11M | 16.27% |
Net na kita | -92.54M | -533.06% |
Net profit margin | -10.31 | -536.42% |
Kita sa bawat share | 1.68 | -37.31% |
EBITDA | 138.86M | -48.29% |
Aktuwal na % ng binabayarang buwis | 16.14% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 2.57B | 41.05% |
Kabuuang asset | 11.53B | 1.83% |
Kabuuang sagutin | 7.36B | -3.55% |
Kabuuang equity | 4.17B | — |
Natitirang share | 61.63M | — |
Presyo para makapag-book | 1.61 | — |
Return on assets | -0.55% | — |
Return on capital | -0.65% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -92.54M | -533.06% |
Cash mula sa mga operasyon | 429.78M | 60.83% |
Cash mula sa pag-invest | -168.93M | 37.87% |
Cash mula sa financing | -813.47M | -1,338.44% |
Net change in cash | -550.92M | -775.52% |
Malayang cash flow | 408.56M | 17.62% |
Tungkol
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Itinatag
2003
Website
Mga Empleyado
2,800
